We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Solid Biosciences (SLDB) Reports Wider-Than Expected Q3 Loss
Read MoreHide Full Article
Solid Biosciences Inc. (SLDB - Free Report) , is engaged in advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne). The company’s lead pipeline candidate is SGT-001, which is being evaluated for the treatment of Duchenne. SGT-001 is a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patients’ muscles and improve the course of the disease.
Solid Biosciences’ surprise record has been mixed so far as its bottom line beat estimates in two of the trailing four quarters and lagged the same on the other two occasions, the average miss being 2.54%. In the last reported quarter, Solid Biosciences witnessed a positive earnings surprise of 2.50%.
Currently, Solid Biosciences has a Zacks Rank #3 (Hold). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Solid Biosciencesreported a loss of 44 cents per share in the third quarter of 2020, which was wider than the Zacks Consensus Estimate of a loss of 32 cents.
Key Stats: In October 2020, Solid Biosciencesand Ultragenyx Pharmaceutical entered into a strategic collaboration to develop and commercialize new gene therapies for Duchenne.The aim of the collaboration is to expand the pipeline of potential gene therapies for patients living with Duchenne. Ultragenyx made a $40 million investment in Solid Solid Biosciencesat a 33% premium.
Share Price Impact: Shares were up 1.9% in pre-market trading.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Solid Biosciences (SLDB) Reports Wider-Than Expected Q3 Loss
Solid Biosciences Inc. (SLDB - Free Report) , is engaged in advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne). The company’s lead pipeline candidate is SGT-001, which is being evaluated for the treatment of Duchenne. SGT-001 is a gene transfer candidate under investigation for its ability to drive functional dystrophin protein expression in patients’ muscles and improve the course of the disease.
Solid Biosciences’ surprise record has been mixed so far as its bottom line beat estimates in two of the trailing four quarters and lagged the same on the other two occasions, the average miss being 2.54%. In the last reported quarter, Solid Biosciences witnessed a positive earnings surprise of 2.50%.
Currently, Solid Biosciences has a Zacks Rank #3 (Hold). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Solid Biosciencesreported a loss of 44 cents per share in the third quarter of 2020, which was wider than the Zacks Consensus Estimate of a loss of 32 cents.
Key Stats: In October 2020, Solid Biosciencesand Ultragenyx Pharmaceutical entered into a strategic collaboration to develop and commercialize new gene therapies for Duchenne.The aim of the collaboration is to expand the pipeline of potential gene therapies for patients living with Duchenne. Ultragenyx made a $40 million investment in Solid Solid Biosciencesat a 33% premium.
Share Price Impact: Shares were up 1.9% in pre-market trading.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>